CAR T Therapy Shows Early Promise in Stiff Person Syndrome
-
November 18, 2026
-
3 min
Clinical Scorecard: Mivocabtagene Autoleucel Studied in Phase 2 Trial for Stiff Person Syndrome
At a Glance
| Category | Detail |
|---|---|
| Condition | Stiff person syndrome (SPS), a rare, progressive autoimmune neurological disorder characterized by muscle stiffness and painful spasms. |
| Key Mechanisms | Mivocabtagene autoleucel is an autologous CD19-directed CAR T-cell therapy. In the trial, complete peripheral B-cell depletion was observed by day five; among patients with elevated GAD65 autoantibodies, median levels fell 56% by week 16. |
| Target Population | Adults with antibody-positive SPS who responded inadequately to previous immunomodulatory treatment. |
| Care Setting | Multicenter, open-label phase 2 trial: 27 participants enrolled, and 26 received a single infusion after low-dose lymphodepleting chemotherapy. |
Key Highlights
- At week 16, the median improvement in the timed 25-foot walk test, the primary efficacy endpoint, was 45.6%.
- More than 80% of participants achieved clinically meaningful improvements in walking speed.
- Eight of 12 participants who initially required walking aids no longer needed them.
- Significant improvements were reported across secondary measures of stiffness, hypersensitivity, disability, and mobility.
- All 26 treated participants remained free of SPS-directed immunomodulatory or immunosuppressive therapies at latest follow-up; median follow-up was 6.5 months.
- The study authors state that long-term follow-up to substantiate durability of benefits is in progress.
Guideline-Based Recommendations
Diagnosis
- The source does not provide diagnostic recommendations.
Management
- The trial administered one infusion of mivocabtagene autoleucel after low-dose lymphodepleting chemotherapy.
- The source describes IVIg, plasmapheresis, and rituximab as existing treatments that often provide incomplete or temporary relief.
Monitoring & Follow-up
- The trial assessed walking ability, stiffness, hypersensitivity, disability, and mobility.
- Biomarker analyses included peripheral B-cell depletion and GAD65 autoantibody levels.
- The study authors state that long-term follow-up to substantiate durability is in progress.
Risks
- Cytokine release syndrome occurred in 92.3% of treated patients; all cases were grade 1 or 2.
- Three patients experienced grade 1 neurotoxicity.
- Grade 3 or 4 neutropenia occurred in five patients (19.2%).
- No deaths or adverse-event-related study discontinuations were reported.
Patient & Prescribing Data
The KYSA-8 trial enrolled 27 adults with antibody-positive SPS and inadequate response to previous immunomodulatory treatment; 26 received treatment.
Participants received one infusion of mivocabtagene autoleucel after low-dose lymphodepleting chemotherapy. All treated participants were free of SPS-directed immunomodulatory or immunosuppressive therapies at latest follow-up; median follow-up was 6.5 months.
Clinical Best Practices
Related Resources & Content
Based on findings from:
CAR T Therapy Shows Early Promise in Stiff Person Syndrome
The Medicine Maker, 2026.
https://themedicinemaker.com/issues/2026/articles/november/car-t-therapy-shows-early-promise-in-stiff-person-syndrome/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.